MPR Rate

Background The PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM inhibition with ET plus CDK4/6i after progression may restore sensitivity. However, most approved agents that target single components of this pathway require direct PI3K-pathway alteration for clinical benefit.

Background Imlunestrant is a next-generation, brain-penetrant, oral SERD. The EMBER-3 trial reported significant progression-free survival (PFS) improvement with imlunestrant over standard therapy (SOC; fulvestrant or exemestane) in patients with ESR1 mutations, and with imlunestrant plus abemaciclib over imlunestrant in all patients, regardless of ESR1 mutation.

The FDA has approved pivekimab sunirine-pvzy (Decnupaz) as a treatment for adult patients with blastic plasmacytoid dendritic cell neoplasms (BPDCNs), according to a news release from the agency.1 The agency based its approval on data from the single-arm phase 1/2 CADENZA trial (NCT03386513), which evaluated the agent in patients with BPDCN in the treatment-naive (n = 33) or relapsed/refractory setting (n = 51).